Sarepta Therapeutics (SRPT) option IV movement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) 30-day option implied volatility is at 71; compared to its 52-week range of 39 to 144 amid the FDA informed Sarepta that it requires modest additional time to complete the review for Biologics License Application for SRP-9001, including final label negotiations and post marketing commitment discussions, and that it anticipates that the review will be complete by June 22.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eaton (ETN) spreaders of November 6 weekly 397.50, November 6 weekly 440, November 420 and November 470 calls as share price down 7%
- Market Vectors Semiconductor ETF (SMH) call put ratio 1 call to 1.7 puts as share price down 4.4%
- Power Solutions (PSIX) call put ratio 1 call to 10.8 puts with a focus on 2500 contracts of November 45 puts
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
